Shy Bladder Syndrome covered by ADA

[chanel]

It could cost U.S. employers between $2 billion and $4 billion to comply with an obscure Americans with Disabilities Act regulation meant to protect workers who are gun-shy in public restrooms.

According to an informal discussion letter the U.S. Equal Employment Opportunity Commission issued in August 2011, “paruresis” — more commonly known as “shy bladder syndrome” — qualifies as a disability under the amended Americans with Disabilities Act.

The International Paruresis Association defines the odd affliction as the “inability to urinate with others present.” The Diagnostic and Statistical Manual of Mental Disorders, the gold-standard of psychiatrists, categorizes it as a social phobia that affects roughly seven percent of the population — approximately 17 million Americans.

The Association alleges that thousands of people who are afflicted by paruresis have been unfairly fired because of their inability to urinate in a public restroom during random drug screening tests.

Read more: Americans with Disabilities Act covers ‘bashful bladder syndrome,’ could cost employers billions | The Daily Caller

This opens a whole range of discussion questions. Has the ADA become out of control? Is the DSMM not to be taken seriously any more? Will classifying "social phobias" as disabilities bankrupt this country?

I'll investigate later, but I believe I read that since the ADA was passed, FEWER handicapped people have been gainfully employed.

Comments?

 

[strollingbones]

turn the damned water on like everyone else...does.....i dont care to use public restrooms....is that covered?

 

[waltky]

Newly approved immunotherapy helps 24 percent of untreated bladder cancer patients...

Roche therapy helps 24 percent of untreated bladder cancer patients: study
June 5, 2016 - A newly approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.

Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become the first option therapy of choice for patients with metastatic bladder cancer, according to a researcher leading the study. Known chemically as atezolizumab, Tecentriq last month won U.S. approval for bladder cancer that had progressed following chemotherapy, becoming the first new drug for the disease in 30 years. The latest study tested the Roche drug, given by injection every three weeks, in 119 patients deemed ineligible for standard cisplatin chemotherapy. Nearly a quarter of the patients experienced at least 30 percent tumor shrinkage with no new lesions, including 7 percent who had no sign of cancer.

Dr. Arjun Balar of New York University Langone Medical Center, the study's lead investigator, said he did not expect to see complete responses in these patients, most of whom had seen their cancer spread to the lungs, liver or bones. "In my opinion it absolutely needs to be considered as a potential new first-line standard of care," said Balar, who presented the data at the American Society of Clinical Oncology scientific meeting in Chicago. Tecentriq belongs to a new class of biotechnology drugs called PD-L1 inhibitors that help the immune system fight cancer by blocking a mechanism tumors use to evade detection. They are similar to PD-1 inhibitors from Merck & Co and Bristol-Myers Squibb that have extended survival in advanced melanoma and lung cancer patients.

At a list price of $12,500 per month, Tecentriq costs roughly the same as Keytruda and Bristol's rival Opdivo. After an average follow-up of 14.4 months into treatment, 75 percent of the responders had not experienced disease progression. Researchers estimate the median overall survival will be 14.8 months. The typical survival prognosis for advanced bladder cancer patients who cannot receive cisplatin is 9 to 10 months, researchers said. The drug is far less toxic than chemotherapy, researchers said, with 6 percent of patients discontinuing therapy due to side effects. Far more patients typically discontinue chemotherapy, and many refuse it altogether.

MORE

 

[strollingbones]

i saw that....hope for the latter stages of a more aggressive bladder cancer....